MOTS-c: The Definitive Research Guide (2026)

MOTS-c is a 16 amino acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene. Its discovery in 2015 by the laboratory of Pinchas Cohen at the University of Southern California overturned decades of thinking about the mitochondrial genome, revealing it as a source of bioactive signaling peptides — not merely a blueprint for oxidative phosphorylation components. This 2026 guide provides a comprehensive research reference: molecular structure, historical context, mechanism of action, published research applications, comparison with other MDPs, reconstitution protocols, EU regulatory framework, and where to buy MOTS-c in Europe without a prescription under Research Use Only (RUO) status.

What is MOTS-c?

MOTS-c stands for Mitochondrial Open Reading Frame of the twelve S rRNA type-c. It is a synthetic peptide with the exact amino acid sequence MRWQEMGYIFYPRKLR and a molecular weight of approximately 2174.6 Da. Unlike classical nuclear-encoded peptide hormones, MOTS-c is derived from a small open reading frame (sORF) inside the mitochondrial genome — specifically within the MT-RNR1 gene that also encodes the 12S ribosomal RNA of mitochondrial ribosomes.

History and discovery

The story of MOTS-c cannot be separated from a broader intellectual shift in the study of the mitochondrial genome. For most of the twentieth century, the ~16.5 kb circular mitochondrial DNA was thought to encode only 13 proteins of the electron transport chain, along with 22 tRNAs and 2 rRNAs — nothing more. The discovery of humanin in 2001 (Hashimoto et al., PNAS) — a 24 amino acid neuroprotective peptide encoded within the 16S rRNA gene — was the first crack in that view.

In 2015, Changhan Lee and colleagues at the University of Southern California, working under the direction of gerontologist Pinchas Cohen, systematically scanned the mitochondrial genome for previously unrecognized small open reading frames. Their landmark paper (Lee C et al., "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance", Cell Metabolism 2015) reported the discovery and functional characterization of MOTS-c. The peptide was named by combining "Mitochondrial ORF" with "twelve S rRNA type-c" — reflecting the fact that its coding sequence sits inside the 12S rRNA gene.

This discovery fundamentally reframed the mitochondrial genome as a source of bioactive signaling peptides that regulate nuclear gene expression and systemic metabolism — a phenomenon now known as mitochondrial-nuclear retrograde signaling. In the years since, more than 300 peer-reviewed publications have investigated MOTS-c across metabolism, aging, exercise physiology, bone biology and cardiovascular research.

Mechanism of action

The primary molecular mechanism described in preclinical research is activation of the AMPK (AMP-activated protein kinase) signaling pathway, the master cellular energy sensor. The Lee et al. (2015) paper demonstrated that MOTS-c does not directly bind AMPK. Instead, it acts upstream via the folate-methionine cycle.

Specifically, MOTS-c inhibits the folate cycle enzyme ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase), which is a key step in de novo purine biosynthesis. Inhibition of ATIC causes accumulation of its substrate AICAR (5-aminoimidazole-4-carboxamide ribonucleoside). AICAR is a well-known endogenous AMPK activator that mimics the effect of AMP on the AMPK regulatory subunit. The resulting AMPK activation triggers a cascade of metabolic effects: increased glucose uptake via GLUT4 translocation, enhanced fatty acid oxidation via inactivation of acetyl-CoA carboxylase, suppression of de novo lipogenesis, and activation of PGC-1alpha-driven mitochondrial biogenesis.

A second, equally striking mechanism was reported by Kim et al. (2018, Cell Metabolism): under conditions of metabolic stress (glucose deprivation, oxidative stress, serum starvation), MOTS-c translocates from the cytoplasm to the nucleus. Once in the nucleus, MOTS-c interacts with chromatin and binds to antioxidant response element (ARE) motifs, promoting the expression of NRF2 target genes and other stress-response transcripts. This makes MOTS-c a genuine mitokine — a mitochondrial-derived signal that directly modulates nuclear transcription in response to organelle-level metabolic state.

Important: all of these effects have been described in preclinical models (cell cultures, animals) and early exploratory human studies. Pepspan sells MOTS-c strictly under Research Use Only (RUO) — it is not an authorized medicine, is not intended for human consumption, and Pepspan provides no clinical guidance.

Research applications

MOTS-c is used in several distinct lines of preclinical research:

1. Metabolic regulation research

The original Lee et al. (2015) characterization showed that daily intraperitoneal MOTS-c administration (5 mg/kg) protected mice from diet-induced obesity, improved glucose tolerance and increased energy expenditure — without reducing caloric intake. This established MOTS-c as a key model peptide for the study of systemic metabolic homeostasis.

2. Insulin sensitivity research

Multiple studies have documented that MOTS-c improves insulin signaling in skeletal muscle by promoting AMPK-dependent GLUT4 translocation. This insulin-independent glucose uptake pathway is of interest for the study of insulin-resistant states.

3. Exercise mimetic research

MOTS-c is now widely characterized as an "exercise mimetic" because it replicates several molecular signatures of physical exercise (AMPK activation, PGC-1alpha activation, GLUT4 translocation). Reynolds et al. (2021, Nature Communications) further demonstrated that acute exercise itself increases circulating MOTS-c levels in both mice and humans, suggesting MOTS-c is part of the endogenous exercise signaling network. See our companion article on MOTS-c as an exercise mimetic.

4. Longevity and aging research

Circulating MOTS-c levels decline with age in mice and humans (Kim et al. 2018). Reynolds et al. (2021) treated 23.5-month-old mice (equivalent to ~70 human years) with MOTS-c and observed improved treadmill performance, grip strength, thermoregulation and body composition — even when treatment was initiated in very old age. This positions MOTS-c as a central research tool in the field of geroscience.

5. Obesity and thermogenesis research

MOTS-c administration in animal models increases energy expenditure via mechanisms that include enhanced thermogenesis and mitochondrial biogenesis in adipose and skeletal muscle tissue, making it a useful probe for research on the neuroendocrine regulation of body weight.

MOTS-c vs other mitochondrial-derived peptides

MOTS-c is one member of a growing family of mitochondrial-derived peptides (MDPs). A brief comparison:

• Humanin — the first MDP discovered (Hashimoto et al. 2001). A 24 amino acid peptide encoded within the 16S rRNA gene (MT-RNR2). Primarily investigated for neuroprotective and anti-apoptotic properties (Alzheimer's-related research, cardioprotection).
• SHLP1-6 (Small Humanin-Like Peptides) — a family of six related peptides, also encoded within the 16S rRNA gene, identified by the Cohen laboratory as part of the systematic scan that also produced MOTS-c. Roles described in metabolic regulation, insulin sensitivity and cell survival research; SHLP2 in particular has been highlighted for metabolic effects.
• MOTS-c — the most-studied MDP as of 2026. A 16 amino acid peptide encoded within the 12S rRNA gene (MT-RNR1). Distinguished by AMPK activation via folate cycle modulation and by its nuclear translocation under stress.

The three MDP families are complementary rather than redundant: humanin sits closer to neuroprotection and cell survival, SHLPs are being characterized as broadly metabolic and cytoprotective, and MOTS-c is the reference peptide for AMPK-driven metabolic and longevity research.

Reconstitution protocol

MOTS-c is shipped as a white lyophilized powder. Standard research reconstitution protocol:

1. Bring both vials to room temperature (20-25 degrees Celsius) before opening. Cold vials cause condensation on the powder.
2. Calculate the diluent volume for the desired concentration. Common example doses:
   • 10mg + 2ml of bac water = 5 mg/ml (concentrated stock)
   • 10mg + 5ml of bac water = 2 mg/ml (dilute working stock)
3. Aseptic technique: disinfect the septa of both vials with 70% isopropanol. Use a sterile syringe.
4. Slowly inject bacteriostatic water along the inner wall of the MOTS-c vial — never directly onto the powder.
5. Swirl gently until fully dissolved. Do not shake vigorously (avoid frothing).
6. Store immediately at 2-8 degrees Celsius. Do not leave at room temperature. Use within 28 days.

In preclinical animal research, doses typically reported range from 0.1 to 5 mg/kg via intraperitoneal injection, with 5 mg/kg/day being the most-published dose (Lee 2015; Reynolds 2021). Cell culture studies commonly use 1-10 micromolar concentrations. Pepspan does not provide dosage recommendations for human use.

Storage protocol

• Lyophilized MOTS-c — stable at -20 degrees Celsius for up to 24 months. Short-term storage at 2-8 degrees Celsius (weeks) is acceptable.
• Reconstituted MOTS-c — store at 2-8 degrees Celsius in the refrigerator. Use within 28 days. Do not freeze the reconstituted solution (freeze-thaw degradation).
• Protect from direct light.
• For long-term stock aliquots, single-use aliquots at -20 degrees Celsius avoid freeze-thaw cycles on the working stock.

Where to buy MOTS-c in Europe

In Europe, MOTS-c is sold as a laboratory reagent under Research Use Only (RUO) status. It is not an EMA-authorized medicine. It does not require a medical prescription for purchase for scientific research purposes. European pharmacies do not stock MOTS-c — the realistic acquisition channel is via specialized research suppliers online.

Pepspan pricing (2026):

• MOTS-c 10mg lyophilized: 89 EUR per vial
• Wholesale (10+ units): automatic 20% discount = 71.20 EUR per unit (712 EUR for 10 vials)
• Free shipping: orders over 100 EUR
• EU shipping: European warehouse, no customs friction to any of the 27 EU/EEA countries
• Janoshik COA included with every order (HPLC, mass spec, endotoxin, microbial)

For research clinics, laboratories or distributors with recurring volume, Pepspan offers custom terms — contact [email protected].

Regulatory framework (EU)

MOTS-c is legally sold across the 27 EU countries and the EEA as a laboratory reagent under the Research Use Only (RUO) framework. It is not authorized as a medicine by the EMA (European Medicines Agency) nor by any national regulator (BfArM in Germany, AEMPS in Spain, ANSM in France, AIFA in Italy, etc.). It cannot be marketed, prescribed or used for human consumption.

By purchasing MOTS-c, the buyer confirms:

• Being a qualified researcher, laboratory professional or working in R&D
• Using the product exclusively for scientific research
• Understanding and accepting the RUO framework and the Pepspan disclaimers

Detailed legal framework: Research peptides EU shipping and legal status.

Buy MOTS-c and related peptides at Pepspan

Frequently asked questions

What is MOTS-c?

MOTS-c is a 16 amino acid mitochondrial-derived peptide (MDP) with sequence MRWQEMGYIFYPRKLR and molecular weight ~2174.6 Da, encoded within a small open reading frame inside the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by the Pinchas Cohen laboratory at USC. It was the first MDP to be systematically characterized as a metabolic regulator.

How does MOTS-c work?

MOTS-c activates the AMPK signaling pathway indirectly, via inhibition of the folate cycle enzyme ATIC and accumulation of the endogenous AMPK activator AICAR. Under metabolic stress, MOTS-c also translocates from the cytoplasm to the nucleus, where it binds ARE motifs and modulates stress-response gene expression. This makes it a genuine mitokine.

Where to buy MOTS-c in Europe?

Pepspan sells MOTS-c 10mg lyophilized at 89 EUR per vial, EU stock, Janoshik COA per lot. Shipping to all 27 EU/EEA countries with no customs friction. Wholesale 10+ vials = automatic 20% discount. No prescription required under the RUO framework.

Is MOTS-c legal in Europe?

Yes. Sold legally across the EU/EEA as a laboratory reagent under Research Use Only (RUO). Not authorized as a medicine by the EMA or by national regulators. No prescription required for research purchase. The buyer must be a qualified researcher.

What is the typical preclinical MOTS-c dosage?

In preclinical animal research: most published studies use 5 mg/kg/day via intraperitoneal injection in mice (Lee 2015; Reynolds 2021). Cell culture: 1-10 micromolar. Reconstitution with bacteriostatic water before use. Pepspan does not provide dosage recommendations for human use.

How to store MOTS-c?

Lyophilized: -20 degrees Celsius for up to 24 months. Reconstituted: 2-8 degrees Celsius, use within 28 days. Never freeze the reconstituted solution. Protect from direct light. Avoid repeated freeze-thaw cycles.

MOTS-c vs other mitochondrial peptides — what is different?

MOTS-c is the most-studied MDP. Humanin (24 aa, from 16S rRNA) is primarily neuroprotective. SHLP1-6 are a family of six peptides also from 16S rRNA, characterized as broadly metabolic/cytoprotective. MOTS-c is unique as the 12S rRNA-derived AMPK activator that also translocates to the nucleus under stress.

How to reconstitute MOTS-c?

Room temperature both vials → calculate diluent volume (10mg + 2ml = 5 mg/ml) → slowly inject bacteriostatic water along the inner wall of the MOTS-c vial (never onto the powder) → swirl gently → store at 2-8 degrees Celsius, use within 28 days.

What is the price of MOTS-c in Europe?

Pepspan: 89 EUR per 10mg vial. Wholesale 10+ units: 71.20 EUR per unit (automatic 20% discount). Free shipping over 100 EUR. VAT included where applicable.